CAR-TCR 2023 – Jason Noon

If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes. For Nona Biosciences, that axis is the antigen binding domain, where they’re enhancing persistence using fully human heavy-chain-only antibodies (H-CABs).

At the event last month Editor in Chief Jonah Comstock caught up with Jason Noon, principal scientist with Nona Biosciences. Noon explained the work his company is doing and how its unique transgenic mouse platform could improve the effectiveness of all kinds of CAR-T therapies. 

The company has also launched a discovery platform that combines rapid screening with next-generation sequencing.

Check out the video below to learn more about the work of Nona Biosciences as well as to hear Noon’s thoughts about the biggest trends in the CAR-T space.

.